Hot News
Tezepelumab as an Oral Corticosteroid-Sparing Therapy in Severe, OCS-Dependent Asthma: Insights from the SUNRISE Trial
Results from the Phase 3 SUNRISE clinical trial, published in The Lancet Respiratory Medicine, highlight Tezepelumab as a potential oral corticosteroid-sparing option for patients with severe asthma.